New trends in Prostate Cancer Imaging

Panagiotis Mourmouris, Titos Markopoulos, Christos Papachristou, Omer Burak Argun, Andreas Skolarikos


Successful imaging of prostate cancer remains a major goal in everyday clinical practice. The widely adapted imaging techniques are limited by their low specificity and sensitivity especially for identification of lymph node or bone metastasis.  A novel imaging technique with better outcomes would provide a significant aid and possibly increase the overall survival of patients suffering from prostate cancer. We review the literature about this interesting topic in an effort to clarify the value of these methods (if any) and their role in prostate cancer diagnosis.


Prostate Cancer; Imaging; mpMRI; PSMA

Full Text:



Walsh PC. 2008 Whitmore Lecture: Radical prostatectomy-where we were and where we are going. Urol Oncol 2009;27:246-250.

Haas GP, Delongchamps NB, Jones RF. Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007;99(19):1484-9. Epub 2007 Sep 25.

Ploussard G, de la Taille A, Moulin M, et al. Conditional Disease-free Survival After Radical Prostatectomy: Recurrence Risk Evolution Over Time. Urology 2016; 94:173-9.

Wolf JS Jr, Cher M, Dall’era M J. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. Urol 1995;153(3 Pt 2): 993-9.

Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007 Apr;243(1): 28-53.

Sedelaar JP, van Roermund JG, van Leenders GL, et al. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. Urology 2001; 57(5): 914-20.

Mitterberger M, Pinggera GM, Pallwein L, et al The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 2007;100(1): 47-50. Epub 2007 Apr 13.

Braeckman J, Autier P, Garbar C, et al. Computer-aided ultrasonography (HistoScanning): A novel technology for locating and characterizing prostate cancer. BJU Int 2008;101(3):293-8. Epub 2007 Oct 8.

Simmons LA, Autier P, Zát’ura F, et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). BJU Int 2012;110(1):28-35.

Morelli G, Pagni R, Mariani C, et al. Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer. J Urol 2011;185(6): 2126-31.

Zhai L, Polascik TJ, Foo WC, et al. Acoustic radiation force impulse imaging of human prostates: Initial in vivo demonstration. Ultrasound Med Biol 2012.

Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011;186(4):1281-5.

Hadaschik BA, Kuru TH, Tulea C, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011;186(6): 2214-20. doi: 10.1016/j.juro.2011.07.102. Epub 2011 Oct 19.

Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: How they are changing the management of prostate cancer. Eur Urol 2011; 59(6): 962-77.

Puech P, Potiron E, Lemaitre L. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology 2009; 74(5): 1094-9.

Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: A critical analysis of the literature. Eur Urol 2012; 61(2): 326-40.

Seitz M, Shukla-Dave A, Bjartell A, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009 Apr;55(4): 801-14.

Hamoen E, de Rooij M, Witjes JA, et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol 2015; 67(6): 1112-21.

Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62(6): 986-96.

Hamoen EH, de Rooij M, Witjes JA, et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Εur Urol 2015;67(6):1112-21.

Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2016;25:pii: S0302-2838(16)30470-5.

Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6 Suppl 10: S13-8.

Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91(3): 528-39.

Sterzing F, Kratochwil C, Fiedler. 68 Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016; 43(1): 34-41.

Habl G, Sauter K, Schiller K, et al. 68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate 2017;77(8): 920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.

Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016; 70(6): 926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28.

Eiber M, Nekolla SG, Maurer T. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging 2015; 40(6): 1769-71.